Non-Small Cell Lung Cancer (NSCLC) | Norton Healthcare

Indication: Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

Sub-indication: Lung Cancer

Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.